Quantbot Technologies LP Acquires 4,527 Shares of Intra-Cellular Therapies Inc (ITCI)

Quantbot Technologies LP raised its holdings in Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 5,520.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,609 shares of the biopharmaceutical company’s stock after purchasing an additional 4,527 shares during the period. Quantbot Technologies LP’s holdings in Intra-Cellular Therapies were worth $100,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Schroder Investment Management Group grew its position in shares of Intra-Cellular Therapies by 0.6% in the 3rd quarter. Schroder Investment Management Group now owns 1,200,906 shares of the biopharmaceutical company’s stock worth $26,060,000 after buying an additional 7,312 shares during the period. DekaBank Deutsche Girozentrale grew its position in shares of Intra-Cellular Therapies by 16.7% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 88,900 shares of the biopharmaceutical company’s stock worth $1,945,000 after buying an additional 12,700 shares during the period. BlackRock Inc. grew its position in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. BlackRock Inc. now owns 3,928,310 shares of the biopharmaceutical company’s stock worth $85,243,000 after buying an additional 133,324 shares during the period. Wasatch Advisors Inc. grew its position in shares of Intra-Cellular Therapies by 1.0% in the 3rd quarter. Wasatch Advisors Inc. now owns 1,928,018 shares of the biopharmaceutical company’s stock worth $41,838,000 after buying an additional 19,787 shares during the period. Finally, Candriam Luxembourg S.C.A. grew its position in shares of Intra-Cellular Therapies by 131.2% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 548,000 shares of the biopharmaceutical company’s stock worth $11,892,000 after buying an additional 311,000 shares during the period. Hedge funds and other institutional investors own 69.53% of the company’s stock.

In related news, Director Joel S. Marcus sold 25,000 shares of the stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $18.24, for a total transaction of $456,000.00. Following the sale, the director now directly owns 21,671 shares of the company’s stock, valued at approximately $395,279.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joel S. Marcus sold 32,000 shares of the stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $18.17, for a total transaction of $581,440.00. Following the sale, the director now directly owns 21,671 shares in the company, valued at $393,762.07. The disclosure for this sale can be found here. Insiders have sold a total of 57,899 shares of company stock worth $1,049,603 over the last three months. 17.40% of the stock is currently owned by insiders.

A number of analysts have recently weighed in on the stock. Leerink Swann reaffirmed an “outperform” rating on shares of Intra-Cellular Therapies in a research report on Friday, October 19th. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Wednesday, November 14th. Canaccord Genuity set a $31.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday. Cantor Fitzgerald set a $32.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Finally, BidaskClub downgraded shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Tuesday, December 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. Intra-Cellular Therapies presently has an average rating of “Buy” and a consensus price target of $28.50.

Shares of ITCI stock opened at $13.55 on Friday. Intra-Cellular Therapies Inc has a one year low of $13.29 and a one year high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.09. As a group, equities analysts expect that Intra-Cellular Therapies Inc will post -3.03 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Quantbot Technologies LP Acquires 4,527 Shares of Intra-Cellular Therapies Inc (ITCI)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/16/quantbot-technologies-lp-acquires-4527-shares-of-intra-cellular-therapies-inc-itci.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

See Also: Insider Trading – What You Need to Know

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply